PMID- 19368852
OWN - NLM
STAT- MEDLINE
DCOM- 20090715
LR  - 20211020
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 455
IP  - 2
DP  - 2009 May 15
TI  - The PKC inhibitor Ro31-8220 blocks acute amphetamine-induced dopamine overflow in 
      the nucleus accumbens.
PG  - 88-92
LID - 10.1016/j.neulet.2009.03.012 [doi]
AB  - Acute administration of the psychostimulant amphetamine increases extracellular 
      levels of dopamine (DA) by reversing the DA transporter on ascending midbrain DA 
      neurons. In vitro studies using striatal synaptosomal, slice and nucleus 
      accumbens (NAcc) tissue preparations have implicated protein kinase C (PKC) in 
      this effect. The present study further examined this effect in vivo by assessing 
      the ability of the PKC inhibitor, Ro31-8220 (10 microM), to inhibit acute 
      amphetamine-induced DA overflow when applied with this drug to the NAcc via 
      reverse dialysis. Amphetamine was applied at a concentration of 30 microM, and 
      the core and shell subregions of the NAcc were assayed separately in freely 
      moving rats. These brain regions play a role in the acute locomotor-activating 
      and motivational effects of amphetamine. Consistent with the findings of previous 
      in vitro experiments, reverse dialysis of Ro31-8220 with amphetamine robustly 
      attenuated the ability of this drug to increase extracellular levels of dopamine 
      in both the core and shell subregions of the NAcc. These results confirm that 
      amphetamine stimulates dopamine overflow via a PKC-dependent mechanism.
FAU - Loweth, Jessica A
AU  - Loweth JA
AD  - Committee on Neurobiology, The University of Chicago, Chicago, IL 60637, USA. 
      jloweth@uchicago.edu
FAU - Svoboda, Robyn
AU  - Svoboda R
FAU - Austin, Jennifer D
AU  - Austin JD
FAU - Guillory, Anitra M
AU  - Guillory AM
FAU - Vezina, Paul
AU  - Vezina P
LA  - eng
GR  - DA-09397/DA/NIDA NIH HHS/United States
GR  - F31 DA022834-02/DA/NIDA NIH HHS/United States
GR  - T32 DA007255-17/DA/NIDA NIH HHS/United States
GR  - R01 DA009397/DA/NIDA NIH HHS/United States
GR  - T32 DA007255/DA/NIDA NIH HHS/United States
GR  - F31-DA-022834/DA/NIDA NIH HHS/United States
GR  - R01 DA009397-12/DA/NIDA NIH HHS/United States
GR  - T32-DA-07255/DA/NIDA NIH HHS/United States
GR  - F31 DA022834/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20090311
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Dopamine Uptake Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - CK833KGX7E (Amphetamine)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - VTD58H1Z2X (Dopamine)
RN  - W9A0B5E78O (Ro 31-8220)
SB  - IM
MH  - Amphetamine/*pharmacology
MH  - Animals
MH  - Dopamine/*metabolism
MH  - Dopamine Plasma Membrane Transport Proteins/drug effects/metabolism
MH  - Dopamine Uptake Inhibitors/*pharmacology
MH  - Indoles/*pharmacology
MH  - Male
MH  - Microdialysis
MH  - Nucleus Accumbens/*drug effects
MH  - Protein Kinase C/antagonists & inhibitors/drug effects
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC2688659
MID - NIHMS111684
EDAT- 2009/04/17 09:00
MHDA- 2009/07/16 09:00
PMCR- 2010/05/15
CRDT- 2009/04/17 09:00
PHST- 2009/01/28 00:00 [received]
PHST- 2009/03/03 00:00 [revised]
PHST- 2009/03/03 00:00 [accepted]
PHST- 2009/04/17 09:00 [entrez]
PHST- 2009/04/17 09:00 [pubmed]
PHST- 2009/07/16 09:00 [medline]
PHST- 2010/05/15 00:00 [pmc-release]
AID - S0304-3940(09)00289-4 [pii]
AID - 10.1016/j.neulet.2009.03.012 [doi]
PST - ppublish
SO  - Neurosci Lett. 2009 May 15;455(2):88-92. doi: 10.1016/j.neulet.2009.03.012. Epub 
      2009 Mar 11.